On the basis of disapproval of the drug ‘Avastin’ by the Food and Drug Administration, the medical insurance company Blue Shield has declared to exclude the medicine from the covering list.

The California–based Blue Shield has posted on its websites that it will not be covering the drug Avastin to any of its customers. The company will support insuring the drug only in rare and critical cases. Presently, the Company covers $ 3.3 million for its members.

The drug Avastin is used to treat patients suffering from breast cancer. The medicine has been claimed to be inappropriate to treat the disease as it can inspire adverse effects. The drug has been disapproved in the month of June, but a final judgment on the drug will be made by the FDA Commissioner Margaret Hamburg in the month of December.

In 2008, the medicine was declared fit for use in the US. That time, the medicine was approved because it proved effective in reducing cancerous cells in breast within a period of 5.5 months.

The medicine was highly effective when provided with chemo sessions.

The recent study, conducted on the medicine, found that the medicine was ineffective in treating patients suffering with advanced stage of the disease.